Literature DB >> 18718755

Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas.

P Mhawech-Fauceglia1, A Allal, K Odunsi, C Andrews, F R Herrmann, B Huard.   

Abstract

A proliferation inducing ligand (APRIL) from the tumour necrosis family (TNF) promotes the natural development of solid tumours in pre-clinical models. Here, we studied the role of APRIL in patients with urothelial bladder, epithelial surface ovarian, and head and neck squamous carcinomas. By using immunohistochemistry, we revealed an upregulation of APRIL expression in lesions from a significant subset of patients compared to corresponding healthy tissues. APRIL upregulation was not due to autocrine production by tumour cells, but rather originated from infiltration of APRIL-producing neutrophils. Heparan sulphate proteoglycan (HSPG) efficiently concentrated secreted APRIL in lesions. Despite this retention, in situ APRIL upregulation did not significantly alter disease-free and overall survivals of carcinoma patients in retrospective studies. This indicates that APRIL is not potent enough to promote the development of solid tumour cells under the pressure of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718755     DOI: 10.1016/j.ejca.2008.07.007

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Tumor necrosis factor superfamily member 13 is a novel biomarker for diagnosis and prognosis and promotes cancer cell proliferation in laryngeal squamous cell carcinoma.

Authors:  Ru Wang; Yichao Guo; Hongzhi Ma; Lin Feng; Qi Wang; Xiaohong Chen; Meng Lian; Haizhou Wang; Jugao Fang
Journal:  Tumour Biol       Date:  2015-09-23

2.  The TNF family member APRIL promotes colorectal tumorigenesis.

Authors:  V Lascano; L F Zabalegui; K Cameron; M Guadagnoli; M Jansen; M Burggraaf; M Versloot; H Rodermond; C van der Loos; C E Carvalho-Pinto; H Kalthoff; J P Medema; M Hahne
Journal:  Cell Death Differ       Date:  2012-06-15       Impact factor: 15.828

3.  Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia.

Authors:  İlay Berke Menteşe; Zeynep Arzu Yegin; Sanem Gökçen; Zübeyde Nur Özkurt; Münci Yağcı
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-10       Impact factor: 0.900

4.  miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.

Authors:  Lin Chen; Haitao Guan; Chunyan Gu; Yali Cao; Jianguo Shao; Feng Wang
Journal:  Tumour Biol       Date:  2015-09-18

5.  The up-regulation expression of APRIL is a marker of glottic malignant disease.

Authors:  Meng Lian; Jugao Fang; Demin Han; Hongzhi Ma; Ru Wang; Fan Yang
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-11-26       Impact factor: 2.503

6.  APRIL, BCMA and TACI proteins are abnormally expressed in non-small cell lung cancer.

Authors:  Hengli Dou; Zhaohua Yan; Meng Zhang; Xiaoxin Xu
Journal:  Oncol Lett       Date:  2016-09-06       Impact factor: 2.967

7.  Serum Levels of APRIL Increase in Patients with Glioma, Meningioma and Schwannoma

Authors:  Hamed Fouladseresht; Seyyed Mohyeddin Ziaee; Nasrollah Erfani; Mehrnoosh Doroudchi
Journal:  Asian Pac J Cancer Prev       Date:  2019-03-26

8.  APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.

Authors:  Russell D Petty; Leslie M Samuel; Graeme I Murray; Graham MacDonald; Terrence O'Kelly; Malcolm Loudon; Norman Binnie; Emad Aly; Aileen McKinlay; Weiguang Wang; Fiona Gilbert; Scot Semple; Elaina S R Collie-Duguid
Journal:  BMC Cancer       Date:  2009-12-11       Impact factor: 4.430

9.  APRIL is overexpressed in cancer: link with tumor progression.

Authors:  Jérôme Moreaux; Jean-Luc Veyrune; John De Vos; Bernard Klein
Journal:  BMC Cancer       Date:  2009-03-16       Impact factor: 4.430

10.  Upregulation of microRNA-383 inhibits the proliferation, migration and invasion of colon cancer cells.

Authors:  Ying Cui; Le-Gao Chen; Hai-Bo Yao; Jun Zhang; Ke-Feng Ding
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.